MiR-1271 upregulated by saturated fatty acid palmitate provokes impaired insulin signaling by repressing INSR and IRS-1 expression in HepG2 cells

Biochemical and Biophysical Research Communications

Volumn 478, Issue 4, 2016, Pages 1786-1791

  Yang, Won Mo ^a   Min, Kyung Ho ^a   Lee, Wan ^a  

^a Dongguk University College of Medicine   (South Korea)

Author keywords

INSR; Insulin resistance; IRS 1; microRNA; miR 1271; Palmitate; Saturated fatty acid

Indexed keywords

INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; MICRORNA; MICRORNA 1271; PALMITIC ACID; SATURATED FATTY ACID; SMALL CYTOPLASMIC RNA; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; FATTY ACID; INSULIN RECEPTOR SUBSTRATE; IRS1 PROTEIN, HUMAN; MIRN1271 MICRORNA, HUMAN; PALMITIC ACID DERIVATIVE;

3' UNTRANSLATED REGION; ARTICLE; BINDING SITE; CONTROLLED STUDY; FAT INTAKE; GLYCOGEN METABOLISM; GLYCOGEN SYNTHESIS; HEPG2 CELL LINE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER CELL; LIVER METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEP-G2 CELL LINE; HUMAN; IMMUNOBLOTTING; LIVER TUMOR; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; UPREGULATION;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; FATTY ACIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HEPATOCYTES; HUMANS; IMMUNOBLOTTING; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; LIVER NEOPLASMS; MICRORNAS; PALMITATES; RECEPTOR, INSULIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY, NUCLEIC ACID; UP-REGULATION;

EID: 84992084080     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.09.029     Document Type: Article

References (31)

1. [1] Kahn, S.E., Hull, R.L., Utzschneider, K.M., Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444 (2006), 840–846.
2. [2] Birkenfeld, A.L., Shulman, G.I., Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 59 (2014), 713–723.
3. [3] Saltiel, A.R., Pessin, J.E., Insulin signaling pathways in time and space. Trends Cell Biol. 12 (2002), 65–71.
4. [4] Samuel, V.T., Shulman, G.I., Mechanisms for insulin resistance: common threads and missing links. Cell 148 (2012), 852–871.
5. [5] Boren, J., Taskinen, M.R., Olofsson, S.O., et al. Ectopic lipid storage and insulin resistance: a harmful relationship. J. Intern. Med. 274 (2013), 25–40.
6. [6] Capurso, C., Capurso, A., From excess adiposity to insulin resistance: the role of free fatty acids. Vasc. Pharmacol. 57 (2012), 91–97.
7. [7] Michael, M.D., Kulkarni, R.N., Postic, C., et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol. Cell 6 (2000), 87–97.
8. [8] Joshi, R.L., Lamothe, B., Cordonnier, N., et al. Targeted disruption of the insulin receptor gene in the mouse results in neonatal lethality. EMBO J. 15 (1996), 1542–1547.
9. [9] Stumvoll, M., Goldstein, B.J., van Haeften, T.W., Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365 (2005), 1333–1346.
10. [10] Bartel, D.P., MicroRNAs: target recognition and regulatory functions. Cell 136 (2009), 215–233.
11. [11] Bushati, N., Cohen, S.M., microRNA functions. Annu. Rev. Cell Dev. Biol. 23 (2007), 175–205.
12. [12] Trajkovski, M., Hausser, J., Soutschek, J., et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474 (2011), 649–653.
13. [13] Jordan, S.D., Kruger, M., Willmes, D.M., et al. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat. Cell. Biol. 13 (2011), 434–446.
14. [14] Kurtz, C.L., Peck, B.C., Fannin, E.E., et al. MicroRNA-29 fine-tunes the expression of key FOXA2-activated lipid metabolism genes and is dysregulated in animal models of insulin resistance and diabetes. Diabetes 63 (2014), 3141–3148.
15. [15] Pike, L.S., Smift, A.L., Croteau, N.J., et al. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim. Biophys. Acta 1807 (2011), 726–734.
16. [16] Yang, W.M., Jeong, H.J., Park, S.W., et al. Obesity-induced miR-15b is linked causally to the development of insulin resistance through the repression of the insulin receptor in hepatocytes. Mol. Nutr. Food Res. 59 (2015), 2303–2314.
17. [17] Ryu, H.S., Park, S.Y., Ma, D., et al. The induction of microRNA targeting IRS-1 is involved in the development of insulin resistance under conditions of mitochondrial dysfunction in hepatocytes. PLoS One, 6, 2011, e17343.
18. [18] Yang, W.M., Jeong, H.J., Park, S.Y., et al. Induction of miR-29a by saturated fatty acids impairs insulin signaling and glucose uptake through translational repression of IRS-1 in myocytes. FEBS Lett. 588 (2014), 2170–2176.
19. [19] Hennessy, E., O'Driscoll, L., Molecular medicine of microRNAs: structure, function and implications for diabetes. Expert. Rev. Mol. Med., 10, 2008, e24.
20. [20] Yang, M., Shan, X., Zhou, X., et al. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. Anticancer Agents Med. Chem. 14 (2014), 884–891.
21. [21] Nurul-Syakima, A.M., Yoke-Kqueen, C., Sabariah, A.R., et al. Differential microRNA expression and identification of putative miRNA targets and pathways in head and neck cancers. Int. J. Mol. Med. 28 (2011), 327–336.
22. [22] Maurel, M., Jalvy, S., Ladeiro, Y., et al. A functional screening identifies five microRNAs controlling glypican-3: role of miR-1271 down-regulation in hepatocellular carcinoma. Hepatology 57 (2013), 195–204.
23. [23] Xiang, X.J., Deng, J., Liu, Y.W., et al. MiR-1271 inhibits cell proliferation, invasion and EMT in gastric cancer by targeting FOXQ1. Cell. Physiol. Biochem. 36 (2015), 1382–1394.
24. [24] Zhou, Z., Niu, X., Li, C., et al. Inhibition of the growth of non-small cell lung cancer by miRNA-1271. Am. J. Transl. Res. 7 (2015), 1917–1924.
25. [25] Liu, X., Ma, L., Rao, Q., et al. MiR-1271 inhibits ovarian Cancer growth by targeting cyclin G1. Med. Sci. Monit. 21 (2015), 3152–3158.
26. [26] Gavrilova, O., Haluzik, M., Matsusue, K., et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 278 (2003), 34268–34276.
27. [27] Lefterova, M.I., Zhang, Y., Steger, D.J., et al. PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. Genes Dev. 22 (2008), 2941–2952.
28. [28] Um, M.Y., Moon, M.K., Ahn, J., et al. Coumarin attenuates hepatic steatosis by down-regulating lipogenic gene expression in mice fed a high-fat diet. Br. J. Nutr. 109 (2013), 1590–1597.
29. [29] Sriburi, R., Bommiasamy, H., Buldak, G.L., et al. Coordinate regulation of phospholipid biosynthesis and secretory pathway gene expression in XBP-1(S)-induced endoplasmic reticulum biogenesis. J. Biol. Chem. 282 (2007), 7024–7034.
30. [30] Sadruddin, S., Arora, R., Resveratrol: biologic and therapeutic implications. J. Cardiometab. Syndr. 4 (2009), 102–106.
31. [31] Moon, Y.A., Liang, G., Xie, X., et al. The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab. 15 (2012), 240–246.